November 1, 2016 Gregg Beloff, Principal Danforth Advisors, LLC
EXHIBIT 10.1
November 1, 2016
Xxxxx Xxxxxx, Principal
Xxxxxxxx Advisors, LLC
00 Xxxxxx Xxxx
Xxxxxxxxxxxx, XX 00000
Dear Xxxxx:
This letter is in reference to the Consulting Agreement between Cerulean Pharma Inc. ("Cerulean") and Xxxxxxxx Advisors, LLC dated May 27, 2015 (as amended, the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meaning given such terms in the Agreement.
In accordance with recent discussions, and consistent with the nonqualified stock option granted to you individually on August 22, 2016, this letter is to document our agreement to further extend the term of the Agreement through August 30, 2018. All other terms of your agreement remain unchanged, and in full force and effect.
If you agree to this extension, please sign below where your name appears and return one fully executed copy to me.
|
|
|
Very truly yours, |
|
|
|
|
|
|
|
CERULEAN PHARMA INC |
|
|
|
|
|
|
|
|
|
|
|
By: /s/ Xxxxxxxxx Xxxxxxxx |
|
|
|
Xxxxxxxxx Xxxxxxxx |
|
|
|
Vice President, General Counsel |
|
Agreed to: |
|
|
|
|
|
|
|
Xxxxxxxx Advisors, LLC |
|
|
|
|
|
|
|
By: /s/ Xxxxx Xxxxxx, Managing |
|
|
|
Xxxxx Xxxxxx, Managing Director |
|
|
Cerulean Pharma Inc. | 00 Xxxxxxxxx Xxxxx X Xxxxxxx, XX 00000 1 P: 000-000-0000 1 F: 000-000-0000
